Aelis Farma

French biotech company Aelis Farma, specializing in the treatment of brain disorders announced positive results Monday from a Phase 1/2 trial of its drug candidate AEF0217 in young adults with Down syndrome. The study, conducted in Spain, assessed the safety, tolerability and potential efficacy of...

French biotechnology company specializing in the treatment of brain disorders Aelis Farma reported Wednesday the results from its clinical Phase 2B trial with AEF0117, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe cannabis use disorder (CUD). The study...

With more and more states and countries embracing cannabis whether for medical or recreational purposes, it could be assumed that the number of people dependent on it would also increase. Even now, the Centers for Disease Control and Prevention warns that estimates show every 3 in 10 people...

Aelis Farma (Paris:AELIS), a clinical stage biopharmaceutical company specializing in the development of treatments for brain diseases, announced positive results from its phase 1 clinical trials in healthy volunteers with its drug candidate AEF0217. AEF0217 is being developed for the treatment of...

Indivior PLC (OTCPK:INVVY) (LON:INDV) announces the enrollment of the first patient in the Phase 2b study of AEF0117 for the treatment of cannabis use disorder (CUD). This follows less than a year after Indivior and Aelis Farma announced a strategic collaboration that includes an exclusive option...